Acute coronary syndrome (ACS) arising from plaque rupture is the leading cause of mortality worldwide. Near-infrared spectroscopy (NIRS) combined with intravascular ultrasound (NIRS-IVUS) is a novel catheter-based intravascular imaging modality that provides a chemogram of the coronary artery wall, which enables the detection of lipid core and specific quantification of lipid accumulation measured as the lipid-core burden index (LCBI) in patients undergoing coronary angiography. Recent studies have shown that NIRS-IVUS can identify vulnerable plaques and vulnerable patients associated with increased risk of adverse cardiovascular events, whereas an increased coronary plaque LCBI may predict a higher risk of future cardiovascular events and periprocedural events. NIRS is a promising tool for the detection of vulnerable plaques in CAD patients, PCI-guidance procedures, and assessment of lipid-lowering therapies. Previous trials have evaluated the impact of statin therapy on coronary NIRS defined lipid cores, whereas NIRS could further be used as a surrogate end point of future ACS in phase II clinical trials evaluating novel anti-atheromatous drug therapies. Multiple ongoing studies address the different potential clinical applications of NIRS-IVUS imaging as a valuable tool for coronary plaque characterization and predictor of future coronary events in CAD patients.
Introduction
Coronary artery disease (CAD) is the leading cause of global mortality and the rupture of an unstable atherosclerotic plaque precedes the majority of acute coronary syndromes (ACS) [1, 2] . Autopsy studies have shown that the putative substrate for most ACS and many cases of sudden cardiac death (SCD) is the rupture of a thin-cap fibroatheroma (TCFA), the so-called "vulnerable plaque," which is defined by a large lipid-rich necrotic core (NC) infiltrated with abundant macrophages and separated from the bloodstream by a thin fibrous cap [3, 4] . The ability to accurately detect index lesions using intravascular imaging is a potential attractive strategy, although it still remains a challenge in daily practice. Conventional coronary angiography (CCA) has been and continues to be an invaluable tool for epicardial coronary stenoses assessment and treatment [5] . Since the coronary angiogram provides a limited "luminogram" view of the coronary arteries, it cannot assess the properties of the arterial wall and thus tends to underestimate the true magnitude of plaque burden, especially in early stages of the disease in which positive vascular remodeling leads to a normal lumen caliber appearance on angiography despite substantial vascular wall plaque [6, 7] . Moreover, angiography provides no information in regard to plaque composition and biological activity, whereas intravascular imaging can potentially circumvent those limitations [8] . Several intravascular-imaging modalities, such as angioscopy, intravascular ultrasound (IVUS), virtual histology (VH), optical coherence tomography (OCT), and near-infrared spectroscopy (NIRS), have been developed throughout the quest of vulnerable plaque to characterize plaque composition and progression, to optimize patient risk stratification and for guiding therapy [9] .
Near-infrared spectroscopy (NIRS) is a novel intravascular-imaging modality that provides chemical assessment related to the presence of cholesterol esters in lipid cores and can generate spectra that distinguishes cholesterol from collagen in coronary plaques through their unique spectroscopic fingerprints [10] . NIRS was first used in 1993 for the detection of lipid content in an experimental animal model [11] , followed by subsequent ex vivo validation in human cadavers [12] . In 2001, a device prototype for intracoronary imaging was developed, which led to multiple case series and clinical studies in the following decade [13] [14] [15] . This technology aims to detect vulnerable lipid-rich plaques (LRPs) by NIRS chemogram [16] , whereas recent literature has demonstrated the association of LRP and culprit lesions in ACS [17, 18] , as well as with nonculprit lesions in ACS [19] , in percutaneous coronary intervention (PCI)-related procedural complications [20, 21] , in plaque regression with statins therapy [22] and with the occurrence of cardiovascular events [23] . NIRS received US Food and Drug Administration (FDA) approval for clinical use in 2008 and for NIRS-IVUS system in 2010, followed by regulatory approval in Europe (CE marked) and Japan in 2011 and 2014, respectively (e.g., Figure 1 ) [24] .
Near-infrared spectroscopy system

Principles of diffuse reflectance NIRS
Spectroscopy is based on the analysis of electromagnetic spectra induced by near-infrared light and provides direct evaluation of plaque composition, which could yield information on plaque vulnerability [13] . Several spectroscopic methods have been investigated for the purpose of identifying atherosclerotic plaque composition, although the commercially available catheter uses diffuse reflectance NIRS [13, 25] . The principle of NIRS relies on the interaction of light in the form of photons with different functional groups of organic molecules in a tissue, which results in reflected light in the NIR region from molecular vibrational energy in the form of oscillations of atoms within their chemical bonds. Photons can be absorbed or scattered by tissue, which determines the amount of light that is detected by the spectrometer. The wavelengths of light in NIRS are approximately in the 800-2500 nm range. Unique combinations of carbon-hydrogen (C-H), nitrogen-hydrogen (N-H), and oxygen-hydrogen (O-H) bonds are responsible for the major absorption of NIR light, whereas each functional group of large complex molecules yields absorption patterns at specific wavelengths, known as the spectroscopic chemical fingerprint, that provides qualitative and quantitative information on sample recognition and tissue characterization (e.g., Figure 2 ) [13, 26, 27] .
Diffuse reflectance NIR spectroscopy has many features that enable in vivo lipid-core plaques (LCP) analysis in coronary arteries. The term "near" indicates the section of infrared that is closer to the visible light region with a longer wavelength and hence a lower energy than visible light. NIR has the ability to identify organic compounds from light penetration through blood and tissue, since hemoglobin and water have relatively low absorbance in the NIR wavelength, avoiding the need to be in contact with tissue or to clear the field of view with saline or contrast flush or by vessel occlusion [13, 26] . Moreover, it can provide simultaneous image acquisition and nondestructive chemical analysis of biologic tissue with rapid acquisition time (<1 s) from an ultrafast laser source, overcoming cardiac motion artifacts. Diffuse
The commercially available NIRS-IVUS imaging system consists of a 3.2-French (F) rapidexchange catheter compatible with 6F-guiding catheters, a pullback and rotation device, and a console that houses the scanning NIR laser, the computer that processes the spectral signal and two monitors [10, 26, 36] . Within the catheter body is a rotating core of optical fibers that deliver near-infrared light and measure the proportion of light reflected back over the range of optical wavelength (800-2500 nm) in the form of an imaging spectrum. The catheter-imaging core enables to collect data rapidly by rotating at 960 rpm with synchronized pullback 
Interpretation of NIRS data
Upon completion of the automated pullback scan, spectral data are automatically analyzed by a computer-based algorithm that transforms NIR spectra into a probability of LCP presence. The probability is mapped to a color pixel that will generate a digital two-dimensional color map of the artery called the NIRS chemogram, which represents the probability of the presence of LCP over the scanned segment of a vessel (Figure 3 ). On the longitudinal chemogram, the x-axis denotes the pullback location (in millimeters) and the y-axis represents the circumferential position (degrees of catheter rotation, from 0 to 360°). For each pixel of 0.1-mm length and 1° angle, the lipid-core probability is calculated from the spectral data collected and quantitatively coded on a color scale transitioning from red (0 = low probability of LCP) to yellow (high probability of LCP), with a probability of 0.60. The threshold required for the detection of LCP of interest was defined in the SPECTACL study according to the high prevalence of LCP (58%) detected in scanned segments that met both criteria of spectral adequacy and similarity from 60 patients undergoing PCI for stable CAD or ACS [10] . Pixels with intermediate data, including those that interfere with the guidewire, appear black. The block chemogram is a semi-quantitative summary metric of the probability that an LCP is present in a 2-mm NIRS chemogram segment that is computed and is displayed as a false color map, thus providing a 1:1 direct comparison of the chemogram with histopathology during validation of the lipid prediction algorithm. The blocks correspond to one of four colors (red (P < 0.57), orange (0.57 ≤ P < 0.84), tan (0.84 ≤ P < 0.98), and yellow (P ≥ 0.98)), which represents the 90 th percentile probability of lipid within the 2-mm segment of the pullback [26, 27, 35, 36] . The 2-mm block chemogram measures were used to compare the NIR spectra to histology in each 2-mm block in a receiver operating characteristic (ROC) curve analysis of diagnostic accuracy, from which LCP probabilities were calculated [10] .
Chemometrics is the methodology applied by NIRS technology to analyze lipid content in atherosclerotic arteries [37] . The NIRS system was used in an extensive ex vivo study using human coronary arteries autopsy specimens to develop an algorithm for LCP detection. NIR spectra and histological data, used as gold standard, were collected from human autopsy hearts to build a calibration model capable of recognizing the NIR spectral shapes unique to LCP (see Section 2. The lipid-core burden index (LCBI) is a measure of the lipid burden within the scanned region, calculated by dividing the number of yellow pixels that exceed an LCP probability of 0.6 per million by the total number of valid pixels in the segment, then multiplied by a factor of 1000 (LCBI range: 0-1000). Other measures can be computed on the chemogram image, such as the LCBI of a region of interest (ROI) and the maximum LCBI of the 4-mm region within the highest lipid burden within the ROI (maxLCBI 4mm ) [26, 27, 35, 36, 39] . It has been shown that a high LCBI detected in coronary plaques is associated with an increased risk of future cardiovascular events and periprocedural complications (see Section 2.6), which suggests that LCBI could be a useful biomarker for risk assessment and therapeutic efficacy in future clinical trials.
Validation of the NIRS-imaging system
Preclinical and autopsy studies
Autopsy, animal, and human studies have been carried out to test the utility and safety of NIRS for the purpose of eventually bringing this technology to patients in the catheterization laboratory. Cassis and Lodder first demonstrated the ability of NIRS to accurately identify low-density lipoprotein (LDL) ex vivo in the aorta of hypercholesterolemic rabbits [11, 41] . Furthermore, Jarros et al. [42] demonstrated that the cholesterol content of human aortic samples determined by NIR spectroscopy correlated strongly with that measured by reversed-phase, high-pressure liquid chromatography (correlation coefficient of 0.96). The ability of NIR spectroscopy to detect atherosclerosis in tissue was also demonstrated in human carotid and coronary arteries. Dempsey et al. [27] used diffuse reflectance NIR spectroscopy for the analysis of human carotid plaques exposed at the time of surgery. Transcutaneous NIRS was performed in the operating room during surgical endarterectomy and a NIRS algorithm was developed, using gel electrophoresis as a reference method, to determine lipoprotein composition in carotid specimen from NIR spectra. Their results showed significant near-IR correlation between certain lipoproteins present in carotid plaques and microscopic findings, including microscopic necrosis and ulceration, plaque hemorrhage, and thrombosis. Moreover, these proteins were easily detectable in patients with a medical history of CAD, coronary artery bypass grafting (CABG), and major surgery, and were also correlated with age, sex, and CAD risk factors. Furthermore, Wang et al. [12] reported that ex vivo direct measurement of lipid/protein ratios in human carotid atherosclerotic specimens from 25 patients correlated with NIRS spectroscopic findings. Thus, the authors concluded that these ratios could further be used to characterize advanced lesion types with superficial necrotic cores in vivo with NIR spectroscopy fitted with a fiber optic probe.
The first study to test the hypothesis that NIR spectroscopy could identify plaque composition and features associated with plaque vulnerability, defined by histology as the presence of lipid pool, thin fibrous cap (<65 μm by ocular micrometry), and inflammatory cell infiltration, was performed in 199 human aortic samples obtained at the time of autopsy [43] . An algorithm was constructed using NIR spectra obtained from 50% of the samples (calibration set) and was then tested on unknown samples (validation set) to determine its ability to identify high-risk features as determined by histology. Spectra associated with each of the three histological features of interest were defined by the results obtained from the calibration set. Since the intention of inventers of the NIRS system was to commercialize a catheter-based instrument that could assess plaques in coronary arteries in vivo and rapidly perform thousands of measurements through blood, Moreno et al. [45] first demonstrated that NIRS could identify lipid-rich plaques in vivo through blood in aorta of rabbits with diet-induced atherosclerosis. The catheter NIR spectroscopy was able to identify lipid areas > or <0.75 mm 2 with 78% sensitivity and 75% specificity. Marshik et al. [46] subsequently demonstrated accurate detection by NIRS spectra of lipid-rich plaques from 26 fresh human aorta samples through various amounts of blood up to a depth of 3 mm, with a sensitivity of 88% and a specificity of 79%. Moreover, the performance of the system was evaluated against histology, with favorable results for the detection of thin-cap fibroatheroma (TCFA) and disrupted plaques through blood, thus supporting the development of a NIR catheter for in vivo coronary arteries TCFA assessment [47] . To evaluate the performance of the system during cardiac motion, a human coronary autopsy specimen was attached at the surface of a beating pig's heart and connected to the porcine circulation [47] . The prototype 3.2-F NIRS catheter was positioned inside the coronary segment and was able to correctly identify a spectrally distinct target attached to the surface of the graft, despite blood flow and cardiac motion [48, 49] .
Autopsy calibration and validation studies
The catheter-based system was improved with the addition of an automated pullback and rotation device allowing the system to circumferentially scan the length of a vessel. Calibration and validation studies of NIRS for the detection of LCP were first performed in human autopsy specimens of coronary arteries [16, 35] . The largest ex vivo study, conducted by Gardner et al. [38] , aimed to evaluate the ability of the NIRS system to detect LCP in human coronary arteries from 84 autopsied hearts. Coronary arteries, obtained from a broad range of patient characteristics and causes of death, were mounted in a tissue fixture and connected to a blood circulation system with physiologic pressure, temperature, and flow. The resulting set of NIRS spectra and corresponding histology data were used to construct and validate an LCP detection algorithm. A total of 86 coronary segments from 33 hearts were used to calibrate the system algorithm for LCP detection and produced prospectively defined end points. The following 51 hearts and 126 segments were used to validate the accuracy of NIRS in the detection of LCPs in a double-blind, prospective study. In order to develop and validate the algorithm for the identification of LCP in coronary arteries, LCP of interest was defined as a fibroatheroma (FA) containing a lipid core of >0.2-mm thick, with a circumferential span of >60° on cross-section and a mean fibrous cap thickness of <450 μm. Prospective validation of the system for the detection of LCP from 51 hearts yielded an area under the ROC curve (AUC) of 0.80 (95% confidence interval (CI): 0.76-0.85) for average lumen diameters of up to 3.0 mm. The detection of any-sized fibroatheroma in an artery segment using the LCBI as a measure of lipid burden resulted in an AUC of 0.86 (95% confidence interval (CI): 0.81-0.91). However, false-positive scan results were obtained when the NIRS system was detecting areas with lipid that did not meet criteria of LCP. Moreover, LCPs with extensive calcifications were not detected by NIRS since the near-infrared light cannot penetrate through calcium and other artifacts [22, 38] .
Clinical validation studies
The first use of the NIRS system in coronary arteries of living humans was performed in six patients undergoing elective PCI for stable angina using an early prototype (2001; Lahey Clinic, Burlington, MA) [13, 16, 40] . No device-related adverse events occurred, showing the safety and feasibility of the system to distinguish spectra measured through blood. However, significant motion artifacts were present due to slow-signal acquisition time (2.5 s). In August 2005, an improved ultrafast NIR system prototype was developed with a faster scanning laser and was later used in a feasibility study of 10 patients in 2006 (Lahey Clinic, Burlington, MA). The trial confirmed the safety of the newer improved device and showed its ability to discriminate between signals obtained in the artery and those from blood alone, with no measurable artifacts of motion [16, 40] . A subsequent pivotal study, the SPECTACL (SPECTroscopic Assessment of Coronary Lipid) clinical study, was performed to validate the accuracy of LCP-detected NIRS signals collected in coronary arteries of 106 patients [10] . The study met its primary end point of demonstrating that spectral data could be safely acquired in coronary arteries of patients with the intravascular NIRS system and that the spectra were equivalent to those gathered from autopsy specimens (success rate of 0.83; 95% confidence interval (CI): 0.70-0.93). Thus, this study supported the feasibility of LCP detection in living patients. Subsequent studies showed intra-and inter-catheter reproducibility of automated interpretation of NIR spectra signals [50, 51] .
Comparison with other intravascular imaging modalities for plaque characterization
The most common cause of acute coronary syndromes (ACS) is believed to be coronary artery thrombosis due to the rupture of lipid-rich "vulnerable plaques." Thin-cap fibroatheroma (TCFA) plaques, which are characterized by a lipid-laden necrotic core with an overlying thin fibrous cap measuring <65 μm, containing few smooth muscle cells but numerous macrophages, are often the substrate for plaque rupture-induced ACS [3, 4] . TCFAs are associated with positive remodeling and thus predominantly located in areas of the coronary tree that show mild to moderate luminal narrowing [52] . As previously outlined, coronary angiography only detects gross stenotic plaques and provides no insight regarding non-ruptured "vulnerable plaques," which limits plaque burden assessment [6] . Intravascular imaging modalities have been developed to fill part of the gap in information provided by coronary angiography and for in vivo detection of LCP [35, 53] . In vivo atherosclerotic imaging could enable to detect, predict, and prevent plaque rupture, improve PCI treatment of flow limiting target lesions, and could identify new therapeutic targets that would prevent future adverse coronary events in CAD patients (e.g., Table 2 ). 
Intravascular ultrasound (IVUS) imaging
Intravascular ultrasound imaging (IVUS) produces cross-sectional images of the lumen and the artery wall in vivo, enabling visual assessment of plaque echogenicity from axial resolution of approximately 100 μm using high-frequency detectors (up to 45 MHz) [9] . IVUS is very accurate in identifying calcifications (sensitivity and specificity of approximately 90%), plaque burden and, unlike coronary angiography, can detect non-protruding plaques as well as positive and negative vascular remodeling [9, 54] . Thus, IVUS is currently the gold standard for atherosclerotic imaging of the coronary arteries in progression/regression plaque trials [9, [55] [56] [57] . In addition to its use as a research tool, IVUS has shown to be of clinical value for the assessment of ambiguous lesions and facilitates optimal PCI procedures by providing reference vessel diameter [9, 58] . A previous study from Lee et al. [59] showed that attenuated lesions on IVUS were more common in ACS patients and were associated with more severe and complex plaque morphology, plaque burden, and higher frequency of no-reflow phenomenon during PCI procedures. Conventional grayscale IVUS has a high sensitivity for detecting lipid deposits (78-95%), visualized as echolucent zones, but a low specificity (30%) [54] . Another limitation of IVUS imaging is the low-axial resolution that does not allow to precisely define thin-cap fibroatheroma (TFCA), whose thickness is usually less than 65 μm in unstable plaques, and thus cannot identify plaques prone to rupture [54] .
Virtual histology (VH) imaging
As compared to conventional invasive ultrasound techniques, radiofrequency (RF) IVUS provides additional information on plaque composition and morphology by spectral analysis of ultrasound backscatter [60] . A color-coded map allows the distinction of different components of atherosclerotic plaques, such as calcification (white), lipid/fibrofatty (light-green), fibrous (green) tissue, and necrotic core (red) [61] . Virtual histology (VH)-IVUS spectral analysis correlates with histopathology studies of plaques and can identify the four plaque components with sensitivity, specificity, and predictive accuracy ranging from 80 to 92% [54, 62, 63] .
VH-IVUS detection of LCPs has been associated with higher incidence of clinical events [64, 65] and periprocedural complications during PCI [66] [67] [68] . Prospective assessment of vulnerable plaques was performed in the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) trial, a multicenter multimodality study that prospectively analyzed by IVUS and IVUS-VH imaging the coronary arteries of 697 ACS patients [64] . Their findings suggested that the presence of TCFA defined by VH-IVUS (hazard ratio (HR), 3.35; 95% CI, 1.77-6.36; P < 0.001), a minimal lumen area of ≤4 mm 2 (HR, 3.21; 95% CI, 1.61-6.42; P =0.001), and a large plaque burden of ≥70% (HR, 5.03; 95% CI, 2.51-10.11; P < 0.001) were independent predictors of major adverse cardiovascular events (MACEs) in nonculprit lesions at 3.4 years follow-up. However, the positive-predictive value was only 18-23%, reflecting MACE's low prevalence. Although this study validated the concept of vulnerable plaque, the lack of specificity and difficulties in image interpretation/measurements prevented these results from changing clinical practice. The VIVA study [65] , as well as the PREDICTION [69] and ATHEROREMO-IVUS [70] studies, subsequently reported similar findings, despite differences with the PROSPECT study regarding inclusion criteria, follow-up duration, definitions of TCFA and MACE. Although RF-IVUS is a validated and promising tool to identify patients and lesions at risk of future ACS, there are limitations regarding axial resolution, accuracy of necrotic core determination, and proper data acquisition and analysis [54, 64, 65] .
Optical coherence tomography (OCT)
Optical coherence tomography is an invasive catheter-based imaging modality that measures the intensity and echo time delay of reflected near-infrared light from internal structures in tissues [71] . This technique provides a resolution of 10-20 μm in vivo, which is largely superior to IVUS. The recent technology uses the optical frequency domain imaging (OFDI), which enables faster pullback speeds without altering image quality and resolution [9] . The use of non-occlusive techniques with flushing of contrast through the guiding catheter during simultaneous image acquisition has partly resolved the issue of light absorption by blood components. OCT can discriminate features of high-risk plaques by evaluating the lipid content and macrophages infiltration, as well as the measurement of fibrous cap thickness [72] . This imaging modality is also used during percutaneous coronary intervention to assess stent apposition, coronary dissections, neoatherosclerosis and in-stent restenosis, mechanisms of plaque disruption in ACS patients, and more recently to evaluate the scaffold of bioabsorbable stents [73, 74] . The main limitation of OCT is the shallow penetration depth (1.0-2.5 mm) into the tissue, which limits proper imaging of biomarkers in atherosclerotic plaques [9, 75] . Other limitations include the lack of standardization of fibrous cap thickness analysis and the inconsistent accuracy in discriminating lipid-rich plaques from similar optical properties, such as macrophages accumulation, which can lead to false-positive results [72] . Regardless of the limitations, intracoronary FD-OCT remains a promising new clinical method for interrogating the microstructural details of the coronary wall [76] .
Near-infrared spectroscopy (NIRS)
In contrast to IVUS, RF-IVUS, and OCT, which collect structural information, NIRS is unique for its ability to directly identify the chemical composition of the arterial wall and assess the presence of the LCP. NIRS detects unequivocal fingerprints from lipid core that is not affected by signal loss behind calcium due to acoustic shadowing, as it can occasionally preclude grayscale IVUS analysis, and the validation of NIRS included both calcified and non-calcified lipid cores in the definition of LCP [38] . NIRS alone does not provide information about structural anatomic parameters, such as vessel remodeling, plaque thickness, lumen area, and calcification [77] . However, as previously mentioned, the combined NIRS-IVUS-imaging catheter allows co-registration of both IVUS and NIRS data, which gives information on both plaque composition and morphology. NIRS-IVUS has shown to improve LCP detection, by comparison to IVUS, in calcified plaques as well as in lesions with small plaque burden [78] . The combined measures of plaque burden and LCBI improved the accuracy of fibroatheroma detection as compared with plaque burden alone by grayscale IVUS. Indeed, Puri et al. [79] conducted an ex vivo NIRS and IVUS-imaging study, performed in 116 coronary arteries of 51 autopsied hearts, whereas lesion-based analysis demonstrated that combining plaque burden and LCBI analysis significantly improves fibroatheroma detection accuracy (c index 0.77, P = 0.028), by comparison to plaque burden alone.
Several studies have compared NIRS with other intravascular-imaging modalities for LCP detection. It was previously shown that large plaque area measured by grayscale IVUS was more often associated with lipid accumulation/LCP detected by NIRS [19, 80] . However, Brugaletta et al. [80] found a weak correlation between the VH necrotic core content of the plaque and the block chemogram probability values (r =0.149), which did not improve after correction for the presence of calcium. In a larger study performed in 131 plaques of 66 vessels, in which 31 plaques (26.7%) were attenuated, the relation between VH-derived percentage necrotic core and NIRS-derived LCBI was not significant (r = 0.16, P = 0.110) [81] .
However, after separation of the plaques according to grayscale IVUS morphology, a positive relationship between VH-derived maximum percentage necrotic core and LCBI was found in non-calcified plaques, but not in calcified plaques. A study conducted in 17 patients who underwent NIRS and OCT imaging showed modest linear correlation between LCBI and maximum lipid arc and lipid index measured by OCT (r 2 = 0.319, P = 0.003, and r 2 = 0.404, P = 0.001, respectively) [82] . Furthermore, Roleder et al. [83] conducted a study which aimed to evaluate the accuracy of NIRS-IVUS-imaging modality to detect TCFA in 60 patients with stable CAD, by comparison to OCT used as the gold-standard reference to define TCFA (cap thickness of <65 μm). They showed that OCT-defined TCFA was characterized by positive vessel remodeling with higher lipid-core burden, while NIRS revealed greater LCBI per 2-mm segment (LCBI 2mm ) >315 with a remodeling index >1.046 as a combined criterion value.
In summary, there are important differences in LCP detection between different intravascular-imaging modalities, owing to their different imaging properties and limitations. As previously mentioned, OCT has the highest resolution but the weakest tissue penetration, limiting assessment of plaque burden and overall plaque volume [84] . While IVUS-VH and OCT require image interpretation for the detection of LCP, NIRS provides automated LCP detection without the need for manual imaging processing, facilitating its use in the catheterization laboratory and enabling rapid ad hoc clinical decision making during procedures. Moreover, OCT and NIRS can image through calcified lesions, whereas IVUS cannot. VH-IVUS can incorrectly misclassify intracoronary stents as calcium surrounded by necrotic core, a major limitation that is not found with OCT and NIRS imaging [84] . From the strengths and weaknesses of each individual imaging modality, it appears that the combination of two or more imaging technologies could improve LCP and vulnerable plaque detection [85] .
NIRS-IVUS clinical applications
There is growing evidence from multiple studies of the clinical applications and value of the NIRS-IVUS imaging modality, including identifying the culprit lesion in ACS, optimizing PCI procedure, identifying plaques at high risk of periprocedural complications, for risk stratification, monitoring lipid-lowering therapy, and assessing plaque vulnerability (e.g., Table 3 ) [86] .
In vivo detection of culprit lesions in ACS
Several studies have evaluated NIRS detection of LCP, shown by an increased LCBI, at the site of culprit lesions associated with coronary events. Madder et al. [17] performed NIRS imaging in culprit vessels of 20 patients with acute ST-segment elevation myocardial infarc- [17] . Among the first 85 STEMI cases, two patients showed culprit lesions that did not contain lipid plaque, but rather a calcified nodule in one case and a coronary dissection in the other [15] .
Similar NIRS findings of lipid burden were observed in culprit lesions of patients in non-ST segment elevation myocardial infarction (NSTEMI) [18, 77] . LCPs are more common in patients with ACS compared to stable angina patients. From the 81 NSTEMI and unstable angina (UA) patients who underwent culprit vessel NIRS imaging prior to stenting, non-STEMI culprit segments had a 3.4-fold greater maxLCBI 4mm than nonculprit segments (448 ± 229 vs. 132 ± 154, P < 0.001) and unstable segments had a 2.6-fold higher maxLCBI 4mm than nonculprit lesions (381 ± 239 vs. 146 ± 175, P < 0.001) [18] . Culprit segments in NSTEMI patients were more often characterized by a maxLCBI 4mm ≥400 than those with UA, with a sensitivity of 63.6% versus 38.5%, respectively. Moreover, a large LCP was identified by NIRS within the culprit lesions of five cases of resuscitated out-of-hospital cardiac arrest that subsequently underwent coronary angiography [87] . There is a stepwise increase in lipid content, represented by maxLCBI 4mm , from nonculprit lesions (0-130), to unstable angina (≈380), to NSTEMI (≈450) and STEMI patients (≈550), supporting the concept of more fibrotic lesions in stable angina and more lipid-rich vulnerable plaque in STEMI, NSTEMI, and sudden death [15] .
NIRS-IVUS evidence of LCP with a large plaque burden suggests that the lesion is a culprit, and that such information could be relevant in patients with ambiguous coronary angiography for efficient treatment management.
Association with cardiovascular risk factors
A recent clinical study has evaluated the association between clinical risk factors and blood characteristics of vascular inflammation and lipid content/LCP visualized by NIRS. de Boer et al. [19] reported the use of NIRS in a nonculprit coronary artery in 208 patients undergoing percutaneous coronary intervention or invasive diagnostic coronary exploration for various indications. It was found that male gender, hypercholesterolemia, and the presence of multivessel CAD were modestly associated with higher LCBI values on NIRS. A history of peripheral vascular disease and/or cerebral disease and the use of beta-blockers were positively associated with LCBI, while biomarkers such as blood lipids and high-sensitivity C-reactive protein were not. All clinical characteristics reflecting patients with high CAD risk explained only 23% of the variability in LCBI. Moreover, the LCBI on NIRS and the percentage area of plaque burden determined by IVUS were modestly correlated (r =0.29). In the light of these results, this study could not address the prognosis value of NIRS-imaging modality.
Methodological caveats could in part explain the low correlation obtained between NIRS and
Developments in Near-Infrared SpectroscopyIVUS imaging, including the use of lower-frequency IVUS catheters (20 MHz), IVUS and NIRS acquisitions performed using different catheters, measurement of a single cross section on IVUS, and the absence of data regarding the reproducibility of repeated NIRS pullbacks and measurements [88] .
Assessing plaque vulnerability and risk stratification
Retrospective autopsy studies have revealed specific histological culprit lesion morphologies in patients suffering from an ACS, which has created an enthusiasm in the use of intravascular coronary artery imaging in search of the "vulnerable plaque" at risk of rupture and endoluminal thrombosis. The thin-cap fibroatheroma (TCFA) is believed to be the precursor lesion of plaque rupture, although there is a lack of prospective robust evidence in the literature [15, 89] . A prospective animal study conducted in an atherosclerotic and diabetic pig model showed that NIRS-IVUS imaging can detect and predict the future development of inflamed fibroatheromas with subsequent validation against postmortem histology [90] . The features of rupture-prone plaques included thinned fibrous cap, increased plaque and necrotic core areas, increased concentration of activated inflammatory cells, and the presence of apoptotic and proliferating cells within the fibrous cap [90] . An autopsy study of 103 coronary arteries from 56 autopsied hearts, aiming to assess grayscale IVUS and NIRS detection of histological fibroatheroma (FA), with histology validation as the gold standard, showed that both superficial IVUS attenuation and NIRS-LCP had a similar high specificity of approximately 95% in detecting FAs, however IVUS showed a low sensitivity (36% vs.
47%; P =001) [91] . The addition of NIRS significantly increased the accuracy of fibroatheroma detection at the minimum lumen area from 75% to 89% among all cross-sections (P < 0.05). When either IVUS attenuation or lipid-rich plaque was present, the sensitivity for prediction of an FA was significantly higher compared with IVUS alone (63% vs. 36%, P < 0.001) and NIRS alone (84% vs. 65%, P < 0.001).
The first prospective human study, published in 2014, has evaluated the association of high LCP by NIRS and cardiovascular events. The ATHEROREMO-NIRS (The European Collaborative Project on Inflammation and Vascular Wall Remodeling in AtherosclerosisNear-Infrared Spectroscopy) trial is a prospective, observational study that aimed to evaluate the prognostic value of NIRS in a nonculprit coronary artery from 203 patients referred for angiography due to stable angina or ACS [92] . The results showed that the 1-year cumulative incidence of all-cause mortality, non-fatal ACS, stroke, and unplanned coronary revascularization was 4-fold increased in patients with an LCBI equal or above to the median value of 43.0 compared to those with an LCBI value below the median (adjusted HR: 4.04; 95% CI: 1.33-12.29; P = 0.01). The association of the LCBI value with primary end point was similar in both stable and ACS patients. Although these results are promising, the number of events in this trial was small, and therefore studies with larger number of events will be required for the validation of vulnerable patient detection with NIRS-IVUS imaging. A more recent NIRS-IVUS single-center registry study was conducted in 121 consecutive patients undergoing combined NIRS and IVUS imaging to evaluate the association of large lipid-rich plaques at non-stented sites in a target vessel and subsequent major adverse cardiovascular and cere-brovascular events (MACCE) [93] . The results showed that the presence of large LCP in a non-stented segment, defined by NIRS maxLCBI 4mm ≥400 at baseline, was associated with a significantly increased risk of future MACCE during follow-up (HR 10.2, 95% CI: 3.4-30.6; P < 0.001). This study, although single center, underpowered, and with limited follow-up, was consistent with the findings of ATHEROREMO-NIRS study, whereas NIRS detection of lipid burden was associated with patient-level risk of future MACCE [93] .
The detection of fibroatheroma could help to identify culprit lesions in ACS patients, predict lesions subject to periprocedural complications, could allow optimal stent selection, and reduce the rate of stent restenosis. Whether the detection of fibroatheroma using NIRS-IVUS will prevent future events is currently being studied in several trials, including the LipidRich Plaque study (LCP; Clinical Trials. 
Optimizing percutaneous coronary intervention procedures
Visual estimation of a coronary stenosis on a two-dimensional (2D) angiography or quantitative coronary angiography (QCA) of lesion lengths is often misleading from image foreshortening and underestimation of plaque burden. IVUS offers accurate length measurement during automated pullback, proximal and distal reference diameter of a vessel, and enables to evaluate the presence and extent of calcifications [26] . The ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) study, a prospective, multicenter, nonrandomized "allcomers" registry of 8583 consecutive patients, showed that IVUS-guidance PCI, performed in 39% of patients, was associated with reduced 1-year rates of MACE (3.1% vs. 4.7%; adjusted HR, 0.70; 95% CI: 0.55-0.88; P = 002), as compared to angiography guidance alone [94] . The benefits of IVUS were observed in patients with ACS and complex lesions, although significant reductions in MACE were present in all patient subgroups, including stable angina and singlevessel disease. Similar results were observed in subsequent meta-analysis [95, 96] .
The use of combined NIRS-IVUS imaging may further optimize stent implantation by accurate identification of lipid margins, and thus cover all the segments with high lipid burden. Dixon et al. [97] analyzed 75 lesions with NIRS imaging and demonstrated that lipid-core plaque extended beyond the angiographic margins of the initial target lesion in 16% of cases. Hanson et al. [98] showed that atheroma, defined as plaque burden >40% or LCP, extended beyond angiographic margins in 52 of the 58 lesions analyzed with NIRS-IVUS (90% of lesions), with a mean lesion length that was significantly longer when assessed by NIRS-IVUS as compared with angiography alone (19.8 ± 7.0 vs. 13.4 ± 5.9 mm; P < 0.0001). Those results suggests that NIRS-IVUS guidance during PCI procedures, as a "red-to-red" stenting strategy, could optimize complete LCP coverage by a stent with the proper length according to the landing zones and thus reduce the risk of edge dissections, stent failure, and subsequent adverse clinical outcomes [26, 39, [99] [100] [101] . Although it seems rationale to implant the edges of a stent in a normal artery segment, the marginal increased risk of stent thrombosis and restenosis with longer stents will require future studies to determine if routine use of NIRS-IVUS for proper stent sizing will improve patient outcomes [102] .
Detection of lipid core in a lesion has also been used as one of the factors to consider in the decision to implant a bare metal stent (BMS) or a drug-eluting stent (DES). Several studies have demonstrated a greater frequency of stent thrombosis after DES implantation when struts were penetrating into a lipid-rich necrotic core plaque rather than in a non-yellow (fibrous) plaque [103, 104] . The absence of struts coverage by the formation of a neointima layer during vessel's healing process was seen with both DES and BMS implantation in lipidrich plaques, which is likely the underlying mechanism of stent thrombosis seen in those patients [105, 106] . Neoatherosclerosis is an important contributor to late-stent thrombosis with newer generation DES, as well as late in-stent restenosis. Histologically, neoatherosclerosis is characterized by the accumulation of lipid-laden macrophages within the neointima with or without necrotic core formation and/or calcification and can occur months to years following stent placement [107] . Originally described in postmortem studies, neoatherosclerosis has more recently been detected by intracoronary imaging. Ali et al. [108] used NIRS and OCT to assess the development of neoatherosclerosis in 65 consecutive patients with symptomatic in-stent restenosis. The prevalence of LCP within neointimal hyperplasia segments was 89% using NIRS versus 62% using OCT. Neoatherosclerosis was associated with significantly reduced minimal cap thickness with plaque rupture occurring exclusively in those patients. Moreover, DES had a higher prevalence and earlier occurrence of neoatherosclerosis, thinner cap, and more lipid burden and density. However, LCP identified by NIRS alone was not associated with periprocedural MI during treatment for in-stent restenosis, which reflects the limited ability of NIRS to differentiate lipid located within the neointimal tissue from a lipid core located underneath stent struts. Nevertheless, postmortem imaging and subsequent histology analysis showed that NIRS could correctly characterize lipid despite the presence of metal struts. Similar findings were reported in a study published by Madder et al.
[109], whereas NIRS was not reliable for neoatherosclerosis detection when used as the sole imaging modality for LCP detection. The NIRS lipid signal could not distinguish neoatherosclerosis from fibroatheroma underlying the stent. No doubt that NIRS can detect coronary LCP, but it seems unlikely suitable as a standalone technique for accurate neoatherosclerosis detection and that the adjunction of IVUS or OCT will be required to determine the position of NIRS lipid signal relative to the underlying stent struts [110] .
It was proposed that the growth of neointima tissue on the top of a vulnerable plaque might increase the thickness of the fibrous cap [103, 110, 111] . Brugaletta et al. [112] reported the ability of bioresorbable vascular scaffold (BVS) implantation to promote the growth of neointimal tissue, which acts as a barrier to isolate vulnerable plaques. An ongoing trial, the PROSPECT II ABSORB sub-study trial (Clinical Trials.org Identifier: NCT021711065), will randomize patients with plaques at high risk of causing future coronary events (plaque burden ≥70%)
to receive an Absorb TM BVS (Abbott Vascular, IL, USA) with optimal medical therapy (OMT) versus OMT alone. This sub-study aims to evaluate the changes in the plaque at 2 years follow-up. Clinically, large LCPs have been shown to be associated with MACE, especially periprocedural myocardial infarction [21] . Whether lipid burden influences long-term outcomes following stent implantation remains elusive.
Prevention of periprocedural complications
Approximately 3-15% of percutaneous coronary interventions are complicated by periprocedural myocardial infarction (PPMI) and no-reflow, in part by distal embolization of intraluminal thrombus and/or lipid-core plaque content, which is associated with adverse long-term outcomes [113, 114] . It was reported that periprocedural MIs are associated with increased atherosclerotic burden and large LCPs [115] [116] [117] [118] . Indeed, embolization of the lipid core after stent implantation in a plaque with high lipid content has been identified as an important cause of periprocedural no-reflow and MI with and without the presence of intracoronary thrombus [118] [119] [120] . A pilot study performed in nine patients using an embolic protection device showed that embolized material consisted in fibrin and platelet aggregates, which reflects the highly thrombogenic content of necrotic core of large atheroma plaques and LCP [98, 120, 121] . In a sub-study of the COLOR (Chemometric Observation of Lipid-Core Plaques of Interest in Native Coronary Arteries) registry, a prospective multicenter observational study aiming to determine a relationship between NIRS-defined high LCBI and periprocedural MI, Goldstein et al. [20] analyzed the cardiac biomarkers of 62 stable patients undergoing PCI. The main findings were that periprocedural MI, defined in the study as a postprocedural elevation above three times the upper limit of normal (ULN) for either creatine kinase-MB (CK-MB) or cTnI measured 4-24 h after PCI, occurred in nine patients (14.5%) and was more common among patients with a maxLCBI 4mm ≥ 500 (7 of 14 patients, 50%) versus patients with a maxLCBI 4mm < 500 (2 of 48 patients, 4.2%). The authors concluded that a high LCP, defined as a maxLCBI 4mm ≥ 500, was associated with periprocedural events. These results are concordant with the registry study conducted by Raghunathan et al. [21] , in which the analysis of 30 patients who underwent pre-procedure NIRS imaging showed a postprocedural increase of CK-MB more than three times the UNL in 27% of patients with a ≥1 yellow blocks (n = 11) as opposed to none in the 19 patients without a yellow block within the stented lesion.
Distal embolization, as an important mechanism of periprocedural MI, was further supported by several studies that have demonstrated a significant decrease in the size of LCP after stenting [122] [123] [124] . Stone et al. showed in the CANARY trial that LCP measured as LCBI by NIRS in the stented vessels reduces with PCI treatment, with a significant reduction of median LCBI from 143.2 before PCI to 17.9 after PCI (P < 0.001) [125] . Moreover, the authors showed that the occurrence of periprocedural MI was associated with higher LCBI, results that are concordant with previous findings [20, 21] .
In order to prevent periprocedural MI during PCI, several strategies were proposed during stenting procedures, including aspiration thrombectomy, embolization distal-protection devices, vasodilators, intensive anticoagulation, and antiplatelet therapies. The CANARY (Coronary Assessment by NIR of Atherosclerotic Rupture-Prone Yellow) trial randomized 85 stable angina patients undergoing stent implantation of a single native coronary lesion and pre-procedure NIRS-defined maxLCBI 4mm ≥ 600 to PCI with or without distal-protection filter [125] . Among the 31 randomized cases with a maxLCBI 4mm ≥ 600, there was no difference in the rates of periprocedural MI with or without the use of distal-protection filter (35.7 vs. 23.5%, respectively; relative risk 1.52; 95% CI: 0.50-4.60, P =0.69). It should be noted that the CANARY trial was ended prematurely due to difficulties in identifying patients suitable Erlinge et al. [129] performed NIRS-IVUS imaging in 18 ACS patients to examine if aspiration thrombectomy reduced the lipid content of ACS culprit plaques. The culprit lipid content was quantified by NIRS-IVUS before and after thrombectomy as the lipid-core burden index (LCBI), and aspirates were examined by histological staining for lipids, calcium, and macrophages. Culprit lesions were found to have high lipid content prior to thrombectomy, which resulted in a 28% reduction in culprit lesion lipid content (pre-aspiration LCBI 466 ± 141 vs. post-aspiration 335 ± 117, P = 0.0001).
As aforementioned, the use of intracoronary NIRS-IVUS imaging for accurate identification of LCP lesions prone to embolize, as well as different treatment strategies, for periprocedural MI prevention are attractive approaches, however their clinical benefits on myocardial salvage and prevention of embolization remains to be demonstrated in future studies.
Monitoring effects of lipid-lowering therapies
It is well known that statin therapy reduces rates of cardiovascular events in secondary prevention. The pharmacological effects of specific lipid-reducing agents that reduce free and esterified cholesterol could be evaluated with NIRS, as it informs on the lipid content of coronary artery plaques over time. The demonstration of markedly reduced LCBI values in a patient after 1 year of high-dose rosuvastatin therapy was the first indication that NIRS-IVUS could be used to evaluate the effect of systemic anti-atherosclerotic medical therapy [130] . In the YELLOW (Reduction in Yellow Plaque by Aggressive Lipid-Lowering Therapy) trial, Kini et al. [22] prospectively randomized 87 patients with multivessel coronary artery disease undergoing PCI with one culprit and one nonculprit hemodynamically significant lesions, defined by fractional flow reserve (FFR <0.80), to receive intensive statin therapy (rosuvastatin of 40 mg daily) or standard lipid-lowering therapy. The nonculprit lesions had a baseline assessment by NIRS-IVUS and FFR, prior to randomization. Rosuvastatin therapy resulted in a significant reduction in the plaque lipid content/maxLCBI 4mm compared to standard therapy. The significant reduction in maxLCBI 4mm associated with intensive statin therapy was observed across subgroups of the study population, based on age, gender, presence of diabetes, and baseline lipid profile. However, no significant changes were observed for the maxLCBI 4mm and LCBI measurements at the lesion site in the standard lipid treatment group at follow-up. Although baseline LCBI was significantly higher in patients randomly allocated to intensive versus standard therapy, the YELLOW trial highlights that LCP measured by NIRS was associated with CAD and that it could be a potential tool to monitor regression of the disease in phase II clinical trials evaluating novel anti-atheromatous therapies.
A similar study of the effect of rosuvastatin treatment on the coronary plaque composition and necrotic core, the IBIS-3 (Integrated Biomarker and Imaging Study 3) trial, failed to demonstrate a significant reduction of necrotic core volume or LCBI under intensive rosuvastatin therapy for 1 year [131] . The effects of high-dose statin therapy are being further investigated in the YELLLOW II trial (Clinical Trials.org Identifier: NCT01837823), a phase II clinical study, that aims to assess the regression of plaque lipid content and changes in plaque morphology from atherosclerotic lesions after 8-12 weeks of high-dose statin therapy by utilizing NIRS, IVUS, and OCT imaging modalities in the coronary arteries.
Limitations of the technology
Near-infrared spectroscopy (NIRS) identifies the chemical signature of the lipid component, specifically lipid core-containing coronary plaque (LCP). The main limitations of NIRS technology are the lack of information regarding the lumen, plaque anatomy, and status of the fibrous cap or its attenuation. Although NIRS may be one of the most sensitive modalities to detect lipid-core plaques, it cannot provide information on the depth of the lipid core. Moreover, the accurate measurement of lipid volume/burden with NIRS has not been validated [132] . To overcome these pitfalls, a new combined imaging catheter adding intravascular ultrasound (IVUS) imaging was developed. However, since intravascular ultrasound has a low sensitivity to visualize lipid inside a plaque, the additional value of this new system will require further evaluation [26] .
The clinical relevance of imaging specific features of the vulnerable plaque for risk stratification and clinical decision making remains unclear. Higher-resolution imaging modalities, such as OCT, better assessed determinants of vulnerable plaques than NIRS; however, there is currently no commercialized system combining OCT and NIRS modalities. The prognostic utility and incremental value of NIRS when associated with biomarkers of plaque vulnerability assessed by IVUS (plaque burden, MLA, and remodeling) remains to be investigated [26, 133] . Many studies have brought evidence that IVUS-guided PCI achieves superior outcomes compared to angiography guidance alone [134] . The potential value of adding NIRS for lipid-rich plaques at risk of embolization and for a complete coverage of LCPs remains to be investigated.
NIRS-IVUS-imaging modality is an invasive diagnostic modality that targets patients in the setting of secondary prevention, thus precluding its utilization for primary prevention, along with other invasive imaging technologies.
Future trials and perspective
NIRS-IVUS-imaging technology is improving and should become a sensitive modality for coronary plaque characterization. A new algorithm for collagen detection has been developed using the same spectroscopy signal, which enables to detect the amount of fibrous tissue over the LCP (thin or thick fibrous cap) [15] . This technology will be further optimized by adding a recently developed, but not yet available, high-resolution IVUS, which will allow to accurately differentiate between thin and thick fibrous caps. Co-registration of NIRS with other imaging modalities is also being developed. The use of combined OCT-NIRS catheters has been recently demonstrated as a proof of concept [15] .
NIRS-IVUS has also been used in the carotid arteries to detect LCP, which could represent a suitable imaging modality to determine the risk of stroke or the risk of complications during carotid stent placement or endarterectomy. However, this new clinical application remains to be validated in future studies [15] .
Multiple prospective outcome studies are currently ongoing to evaluate the ability of NIRS-IVUS imaging to detect vulnerable plaques that are likely to cause future adverse events. Among those studies are the LRP trial (Lipid-rich Plaque Study; Clinical Trial.org Identifier: NCT02033694), the PROSPECT II ABSORB trial (Providing Regional Observations to Study Predictors of Events in the Coronary Tree II; Clinical Trial.org Identifier: NCT02171065), and the ORACLE-NIRS trial (Lipid-core plaque association with clinical events: a near-infrared spectroscopy study; Clinical Trial.org Identifier: NCT02265146). The YELLOW II trial (NCT01837823), which aims to evaluate the effects of rosuvastatin treatment on lipid content after 8-10 weeks of treatment regimen, has completed patient enrolment but results are still pending. Another trial has been completed and awaiting for results publication, the NIRS-TICAGRELOR trial (Clinical Trial.org Identifier: NCT02282332), which aims to evaluate the effect of the P2Y12 inhibitor ticagrelor (AstraZeneca, Cambridge, England) on plaque stabilization and reduction of inflammation by NIRS-defined reduction of LCBI in patients on longterm statin therapy undergoing non-urgent PCI.
Conclusion
NIRS is a promising tool for the detection of vulnerable plaques in CAD patients, PCI-guidance procedures, and assessment of lipid-lowering therapies. NIRS-IVUS has been shown to be a reliable and reproducible modality for the detection of intracoronary LCPs, with validation using the current gold-standard, histology. It has already been shown that this imaging modality is highly specific for identifying NSTEMI and STEMI culprit plaques, that it can be used to follow the progression of vulnerable plaques over time, and to evaluate the effect of lipid-lowering therapies and intracoronary devices. Moreover, preliminary data have shown that NIRS-IVUS-imaging technology can identify vulnerable patients. Multiple ongoing clinical trials will hopefully validate this tool for vulnerable plaque and patient detection, as well as for treatment management and follow-up of patients with CAD. 
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